Fig. 2: ProCTLA-4 shows better efficacy in tumor controlling.

a, b MC38 tumor-bearing male hCTLA-4 KI mice were i.p. treated with PBS (CTR) (n = 8), 100 μg Ipilimumab (Ipi) (n = 9) or equimolar ProCTLA-4 (n = 8) on days 14, 17, and 20. The tumor growth (a) and the percentage of tumor regression (b) were recorded. c B16F10 tumor-bearing male hCTLA-4 KI mice were treated with CTR, 100 μg Ipi, or equimolar ProCTLA-4 (n = 5/group) on days 12, 15, 18, 21. The tumor growth was measured. d A549 tumor-bearing humanized male NSG-SGM3 mice engrafted with CD34⁺ human hematopoietic cells were i.p. treated with CTR (n = 3), 100 μg Ipi (n = 4), or equimolar ProCTLA-4 (n = 4) on days 15, 18, 21 and 24. The tumor growth was monitored. e MC38 tumor-bearing male C57BL/6 mice were i.p. treated with CTR, 100 μg anti-mouse CTLA4 antibody (mCTLA-4), or equimolar mouse ProCTLA-4 (mProCTLA-4) (n = 6/group) on days 11 and 200 μg mCTLA-4 or equimolar mProCTLA-4 on day14. The tumor growth was recorded. f CT26 tumor-bearing male BALB/c mice were treated with CTR, 100 μg mCTLA4, or equimolar mProCTLA-4 (n = 5/group) on day 13. Tumor growth was measured. Data in panels (a, b) are pulled from two independent experiments. Data in panels (c–f) are representative of two independent experiments. Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test (a, c–f), or log-rank (Mantel-Cox) test (b).